Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

(2023) Maria Vieito et al.   CLINICAL CANCER RESEARCH

Management of patients with lower-risk myelodysplastic syndromes

(2022) Andrew M. Brunner et al.   Blood Cancer Journal

Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin

(2021) Alan F. List et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

(2021) David P. Steensma et al.   LEUKEMIA

A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies

(2021) Manish R. Patel et al.   BLOOD

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity

(2021) Dirk Brehmer et al.   MOLECULAR CANCER THERAPEUTICS

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

(2020) Pierre Fenaux et al.   NEW ENGLAND JOURNAL OF MEDICINE

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study

(2020) David P. Steensma et al.   JOURNAL OF CLINICAL ONCOLOGY

438OMETEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours

(2019) L L Siu et al.   ANNALS OF ONCOLOGY

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

(2019) Justin M. Watts et al.   BLOOD

H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers

(2018) Michael Seiler et al.   NATURE MEDICINE

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

(2018) Uwe Platzbecker et al.   BLOOD

PRMT5-Dependent Methylation of the TIP60 Coactivator RUVBL1 Is a Key Regulator of Homologous Recombination

(2017) Thomas L. Clarke et al.   MOLECULAR CELL

Arginine Methylation: The Coming of Age

(2017) Roméo S. Blanc et al.   MOLECULAR CELL

Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome

(2017) Cara Lunn Shirai et al.   Nature Communications

Association between Transfusion Status and Overall Survival in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis

(2016) Sue Harnan et al.   ACTA HAEMATOLOGICA

Physiologic Expression of Sf3b1 K700E Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation

(2016) Esther A. Obeng et al.   CANCER CELL

New insights into transfusion-related iron toxicity: Implications for the oncologist

(2016) John B. Porter et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis

(2016) Daichi Inoue et al.   GENES & DEVELOPMENT

Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts

(2016) A Mupo et al.   LEUKEMIA

Wild-Type U2AF1 Antagonizes the Splicing Program Characteristic of U2AF1-Mutant Tumors and Is Required for Cell Survival

(2016) Dennis Liang Fei et al.   PLoS Genetics

SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition

(2015) Eunhee Kim et al.   CANCER CELL

Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo

(2015) Cara Lunn Shirai et al.   CANCER CELL

The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond

(2015) Nicole Stopa et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis

(2015) Fan Liu et al.   JOURNAL OF CLINICAL INVESTIGATION

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

(2015) A Toma et al.   LEUKEMIA

How we treat lower-risk myelodysplastic syndromes

(2013) P. Fenaux et al.   BLOOD

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

(2013) C Kelaidi et al.   LEUKEMIA